ADHD with Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical and Pharmacological Aspects Across the Lifespan

Federico       Mucci; Maria    Teresa    Avella; Donatella       Marazziti
Abstract

Background: Attention deficit hyperactivity (ADHD) disorder is a neurodevelopmental disorder characterized by inattention, hyperactivity, disruptive behaviour, and impulsivity. Despite considered typical of children for a long time, the persistence of ADHD symptoms in adulthood gained increasing interest during the last decades. Indeed, its diagnosis, albeit controversial, is rarely carried out even because ADHD is often comorbid with several other psychiatric diosrders, in particular with bipolar disorders (BDs), a condition that complicates the clinical picture, assessment and treatment.
Aims: The aim of this paper was to systematically review the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood.
Discussion: The pharmacology of ADHD-BD in adults is still empirical and influenced by the individual experience of the clinicians. Stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants are useful when a substance abuse history is detected, although they require some weeks in order to be fully effective. In any case, an in-depth diagnostic and clinical evaluation of the single individual is mandatory.
Conclusion: The comorbidity of ADHD with BD is still a controversial matter, as it is the notion of adult ADHD as a distinct nosological category. Indeed, some findings highlighted the presence of common neurobiological mechanisms and overlapping clinical features, although disagreement does exist. In any case, while expecting to disentangle this crucial question, a correct management of this comorbidity is essential, which requires the co-administration of mood stabilizers. Further controlled clinical studies in large samples of adult ADHD-BD patients appear extremely urgent in order to better define possible therapeutic guidelines, as well as alternative approaches for this potentially invalidating condition.
Keywords: ADHD, bipolar disorders, comorbidity, neurobiology, pharmacological treatments, stimulants.
« Previous
[1] 

American psychiatric association committee on nomenclature and statistics. Diagnostic and Statistical Manual of Mental Disorders, 5th ed; American Psychiatric Press: Washington, DC, 2014. 
[2] 
Spencer, T.J.; Biederman, J.; Mick, E. Attention-deficit/hyperactivity disorder: Diagnosis, lifespan, comorbidities, and neurobiology. J. Pediatr. Psychol.,  2007, 32(6), 631-642.
[http://dx.doi.org/10.1093/jpepsy/jsm005] [PMID:  17556405] 
[3] 
Katzman, M.A.; Bilkey, T.S.; Chokka, P.R.; Fallu, A.; Klassen, L.J. Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry,  2017, 17(1), 302.
[http://dx.doi.org/10.1186/s12888-017-1463-3] [PMID:  28830387] 
[4] 
Kessler, R.C.; Adler, L.A.; Barkley, R.; Biederman, J.; Conners, C.K.; Faraone, S.V.; Greenhill, L.L.; Jaeger, S.; Secnik, K.; Spencer, T.; Ustün, T.B.; Zaslavsky, A.M. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol. Psychiatry,  2005, 57(11), 1442-1451.
[http://dx.doi.org/10.1016/j.biopsych.2005.04.001] [PMID:  15950019] 
[5] 
Wender, P.H.; Wolf, L.E.; Wasserstein, J. Adults with ADHD. An overview. Ann. N. Y. Acad. Sci.,  2001, 931, 1-16.
[http://dx.doi.org/10.1111/j.1749-6632.2001.tb05770.x] [PMID:  11462736] 
[6] 
Caye, A.; Rocha, T.B.; Anselmi, L.; Murray, J.; Menezes, A.M.; Barros, F.C.; Gonçalves, H.; Wehrmeister, F.; Jensen, C.M.; Steinhausen, H.C.; Swanson, J.M.; Kieling, C.; Rohde, L.A. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: Evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry,  2016, 73(7), 705-712.
[http://dx.doi.org/10.1001/jamapsychiatry.2016.0383] [PMID:  27192050] 
[7] 
Agnew-Blais, J.C.; Polanczyk, G.V.; Danese, A.; Wertz, J.; Moffitt, T.E.; Arseneault, L. Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiatry,  2016, 73(7), 713-720.
[http://dx.doi.org/10.1001/jamapsychiatry.2016.0465] [PMID:  27192174] 
[8] 
Polanczyk, G.V.; Willcutt, E.G.; Salum, G.A.; Kieling, C.; Rohde, L.A. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int. J. Epidemiol.,  2014, 43(2), 434-442.
[http://dx.doi.org/10.1093/ije/dyt261] [PMID:  24464188] 
[9] 
Biederman, J.; Mick, E.; Faraone, S.V. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. Am. J. Psychiatry,  2000, 157(5), 816-818.
[http://dx.doi.org/10.1176/appi.ajp.157.5.816] [PMID:  10784477] 
[10] 
Larsson, H.; Dilshad, R.; Lichtenstein, P.; Barker, E.D. Developmental trajectories of DSM-IV symptoms of attention-deficit/hyperactivity disorder: genetic effects, family risk and associated psychopathology. J. Child Psychol. Psychiatry,  2011, 52(9), 954-963.
[http://dx.doi.org/10.1111/j.1469-7610.2011.02379.x] [PMID:  21434915] 
[11] 
Asherson, P.; Young, A.H.; Eich-Höchli, D.; Moran, P.; Porsdal, V.; Deberdt, W. Differential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. Curr. Med. Res. Opin.,  2014, 30(8), 1657-1672.
[http://dx.doi.org/10.1185/03007995.2014.915800] [PMID:  24804976] 
[12] 
Bálint, S.; Czobor, P.; Komlósi, S.; Mészáros, A.; Simon, V.; Bitter, I. Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. Psychol. Med.,  2009, 39(8), 1337-1345.
[http://dx.doi.org/10.1017/S0033291708004236] [PMID:  18713489] 
[13] 
Retz, W.; Stieglitz, R.D.; Corbisiero, S.; Retz-Junginger, P.; Rösler, M. Emotional dysregulation in adult ADHD: what is the empirical evidence? Expert Rev. Neurother.,  2012, 12(10), 1241-1251.
[http://dx.doi.org/10.1586/ern.12.109] [PMID:  23082740] 
[14] 
Bond, D.J.; Hadjipavlou, G.; Lam, R.W.; McIntyre, R.S.; Beaulieu, S.; Schaffer, A.; Weiss, M. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann. Clin. Psychiatry,  2012, 24(1), 23-37.
[PMID:  22303520] 
[15] 
Klassen, L.J.; Katzman, M.A.; Chokka, P. Adult ADHD and its comorbidities, with a focus on bipolar disorder. J. Affect. Disord.,  2010, 124(1-2), 1-8.
[http://dx.doi.org/10.1016/j.jad.2009.06.036] [PMID:  19683348] 
[16] 
Nierenberg, A.A.; Miyahara, S.; Spencer, T.; Wisniewski, S.R.; Otto, M.W.; Simon, N.; Pollack, M.H.; Ostacher, M.J.; Yan, L.; Siegel, R.; Sachs, G.S. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol. Psychiatry,  2005, 57(11), 1467-1473.
[http://dx.doi.org/10.1016/j.biopsych.2005.01.036] [PMID:  15950022] 
[17] 
Becker, S.P.; Burns, G.L.; Garner, A.A.; Jarrett, M.A.; Luebbe, A.M.; Epstein, J.N.; Willcutt, E.G. Sluggish cognitive tempo in adults: Psychometric validation of the adult concentration inventory. Psychol. Assess.,  2018, 30(3), 296-310.
[http://dx.doi.org/10.1037/pas0000476] [PMID:  28383930] 
[18] 
Flannery, A.J.; Luebbe, A.M.; Becker, S.P. Sluggish cognitive tempo is associated with poorer study skills, more executive functioning deficits, and greater impairment in college students. J. Clin. Psychol.,  2017, 73(9), 1091-1113.
[http://dx.doi.org/10.1002/jclp.22406] [PMID:  27764528] 
[19] 
Becker, S.P.; Marshall, S.A.; McBurnett, K. Sluggish cognitive tempo in abnormal child psychology: an historical overview and introduction to the special section. J. Abnorm. Child Psychol.,  2014, 42(1), 1-6.
[http://dx.doi.org/10.1007/s10802-013-9825-x] [PMID:  24272365] 
[20] 
Flannery, A.J.; Becker, S.P.; Luebbe, A.M. Does emotion dysregulation mediate the association between sluggish cognitive tempo and college students’ social impairment? J. Atten. Disord.,  2016, 20(9), 802-812.
[http://dx.doi.org/10.1177/1087054714527794] [PMID:  24691529] 
[21] 
Sternat, T.; Katzman, M.A. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr. Dis. Treat.,  2016, 12, 2149-2164.
[http://dx.doi.org/10.2147/NDT.S111818] [PMID:  27601909] 
[22] 
Merikangas, K.R.; Jin, R.; He, J.P.; Kessler, R.C.; Lee, S.; Sampson, N.A.; Viana, M.C.; Andrade, L.H.; Hu, C.; Karam, E.G.; Ladea, M.; Medina-Mora, M.E.; Ono, Y.; Posada-Villa, J.; Sagar, R.; Wells, J.E.; Zarkov, Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry,  2011, 68(3), 241-251.
[http://dx.doi.org/10.1001/archgenpsychiatry.2011.12] [PMID:  21383262] 
[23] 
Moreno, C.; Laje, G.; Blanco, C.; Jiang, H.; Schmidt, A.B.; Olfson, M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch. Gen. Psychiatry,  2007, 64(9), 1032-1039.
[http://dx.doi.org/10.1001/archpsyc.64.9.1032] [PMID:  17768268] 
[24] 
Marangoni, C.; De Chiara, L.; Faedda, G.L. Bipolar disorder and ADHD: comorbidity and diagnostic distinctions. Curr. Psychiatry Rep.,  2015, 17(8), 604.
[http://dx.doi.org/10.1007/s11920-015-0604-y] [PMID:  26084666] 
[25] 
Leverich, G.S.; Post, R.M.; Keck, P.E., Jr; Altshuler, L.L.; Frye, M.A.; Kupka, R.W.; Nolen, W.A.; Suppes, T.; McElroy, S.L.; Grunze, H.; Denicoff, K.; Moravec, M.K.; Luckenbaugh, D. The poor prognosis of childhood-onset bipolar disorder. J. Pediatr.,  2007, 150(5), 485-490.
[http://dx.doi.org/10.1016/j.jpeds.2006.10.070] [PMID:  17452221] 
[26] 
Wingo, A.P.; Ghaemi, S.N. A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. J. Clin. Psychiatry,  2007, 68(11), 1776-1784.
[http://dx.doi.org/10.4088/JCP.v68n1118] [PMID:  18052572] 
[27] 
McIntyre, R.S.; Kennedy, S.H.; Soczynska, J.K.; Nguyen, H.T.; Bilkey, T.S.; Woldeyohannes, H.O.; Nathanson, J.A.; Joshi, S.; Cheng, J.S.; Benson, K.M.; Muzina, D.J. Attention deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international
mood disorders collaborative project. Prim.
Care Companion J. Clin. Psychiatry,,  2010, 12(3), PCC.09m00861.
[http://dx.doi.org/10.4088/PCC.09m00861gry] [PMID:  20944770] 
[28] 
Halmøy, A.; Halleland, H.; Dramsdahl, M.; Bergsholm, P.; Fasmer, O.B.; Haavik, J. Bipolar symptoms in adult attention-deficit/hyperactivity disorder: a cross-sectional study of 510 clinically diagnosed patients and 417 population-based controls. J. Clin. Psychiatry,  2010, 71(1), 48-57.
[http://dx.doi.org/10.4088/JCP.08m04722ora] [PMID:  20129005] 
[29] 
McGough, J.J.; Smalley, S.L.; McCracken, J.T.; Yang, M.; Del’Homme, M.; Lynn, D.E.; Loo, S. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am. J. Psychiatry,  2005, 162(9), 1621-1627.
[http://dx.doi.org/10.1176/appi.ajp.162.9.1621] [PMID:  16135620] 
[30] 
Fombonne, E. Epidemiology of pervasive developmental disorders. Pediatr. Res.,  2009, 65(6), 591-598.
[http://dx.doi.org/10.1203/PDR.0b013e31819e7203] [PMID:  19218885] 
[31] 
Polanczyk, G.; Jensen, P. Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child Adolesc. Psychiatr. Clin. N. Am.,  2008, 17(2), 245-260.
[http://dx.doi.org/10.1016/j.chc.2007.11.006] [PMID:  18295145] 
[32] 
Singh, I. Beyond polemics: science and ethics of ADHD. Nat. Rev. Neurosci.,  2008, 9(12), 957-964.
[http://dx.doi.org/10.1038/nrn2514] [PMID:  19020513] 
[33] 
Goodman, D.W. The consequences of attention-deficit/hyperactivity disorder in adults. J. Psychiatr. Pract.,  2007, 13(5), 318-327.
[http://dx.doi.org/10.1097/01.pra.0000290670.87236.18] [PMID:  17890980] 
[34] 
Torralva, T.; Gleichgerrcht, E.; Torrente, F.; Roca, M.; Strejilevich, S.A.; Cetkovich, M.; Lischinsky, A.; Manes, F. Neuropsychological functioning in adult bipolar disorder and ADHD patients: a comparative study. Psychiatry Res.,  2011, 186(2-3), 261-266.
[http://dx.doi.org/10.1016/j.psychres.2010.08.007] [PMID:  20832868] 
[35] 
Scheffer, R.E. Concurrent ADHD and bipolar disorder. Curr. Psychiatry Rep.,  2007, 9(5), 415-419.
[http://dx.doi.org/10.1007/s11920-007-0054-2] [PMID:  17915082] 
[36] 
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med.,  2009, 6(7)e1000100
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID:  19621070] 
[37] 
Gallo, E.F.; Posner, J. Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms. Lancet Psychiatry,  2016, 3(6), 555-567.
[http://dx.doi.org/10.1016/S2215-0366(16)00096-1] [PMID:  27183902] 
[38] 
Biederman, J.; Munir, K.; Knee, D.; Armentano, M.; Autor, S.; Waternaux, C.; Tsuang, M. High rate of affective disorders in probands with attention deficit disorder and in their relatives: a controlled family study. Am. J. Psychiatry,  1987, 144(3), 330-333.
[http://dx.doi.org/10.1176/ajp.144.3.330] [PMID:  3826433] 
[39] 
Biederman, J.; Faraone, S.V.; Keenan, K.; Tsuang, M.T. Evidence of familial association between attention deficit disorder and major affective disorders. Arch. Gen. Psychiatry,  1991, 48(7), 633-642.
[http://dx.doi.org/10.1001/archpsyc.1991.01810310051009] [PMID:  2069494] 
[40] 
Hirshfeld-Becker, D.R.; Biederman, J.; Henin, A.; Faraone, S.V.; Dowd, S.T.; De Petrillo, L.A.; Markowitz, S.M.; Rosenbaum, J.F. Psychopathology in the young offspring of parents with bipolar disorder: a controlled pilot study. Psychiatry Res.,  2006, 145(2-3), 155-167.
[http://dx.doi.org/10.1016/j.psychres.2005.08.026] [PMID:  17083985] 
[41] 
Ghanizadeh, A.; Mohammadi, M.R.; Moini, R. Comorbidity of psychiatric disorders and parental psychiatric disorders in a sample of Iranian children with ADHD. J. Atten. Disord.,  2008, 12(2), 149-155.
[http://dx.doi.org/10.1177/1087054708314601] [PMID:  18319376] 
[42] 
Birmaher, B.; Axelson, D.; Goldstein, B.; Monk, K.; Kalas, C.; Obreja, M.; Hickey, M.B.; Iyengar, S.; Brent, D.; Shamseddeen, W.; Diler, R.; Kupfer, D. Psychiatric disorders in preschool offspring of parents with bipolar disorder: The Pittsburgh Bipolar Offspring Study (BIOS). Am. J. Psychiatry,  2010, 167(3), 321-330.
[http://dx.doi.org/10.1176/appi.ajp.2009.09070977] [PMID:  20080982] 
[43] 
Kim, J.W.; Yu, H.; Ryan, N.D.; Axelson, D.A.; Goldstein, B.I.; Goldstein, T.R.; Diler, R.S.; Monk, K.; Hickey, M.B.; Sakolsky, D.J.; Merranko, J.A.; Birmaher, B. Longitudinal trajectories of ADHD symptomatology in offspring of parents with bipolar disorder and community controls. J. Clin. Psychiatry,  2015, 76(5), 599-606.
[http://dx.doi.org/10.4088/JCP.14m09095] [PMID:  26035189] 
[44] 
Krause, J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev. Neurother.,  2008, 8(4), 611-625.
[http://dx.doi.org/10.1586/14737175.8.4.611] [PMID:  18416663] 
[45] 
Volkow, N.D.; Wang, G.J.; Tomasi, D.; Kollins, S.H.; Wigal, T.L.; Newcorn, J.H.; Telang, F.W.; Fowler, J.S.; Logan, J.; Wong, C.T.; Swanson, J.M. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J. Neurosci.,  2012, 32(3), 841-849.
[http://dx.doi.org/10.1523/JNEUROSCI.4461-11.2012] [PMID:  22262882] 
[46] 
Berk, M.; Dodd, S.; Kauer-Sant’anna, M.; Malhi, G.S.; Bourin, M.; Kapczinski, F.; Norman, T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl.,  2007, (434), 41-49.
[http://dx.doi.org/10.1111/j.1600-0447.2007.01058.x] [PMID:  17688462] 
[47] 
Dunlop, B.W.; Nemeroff, C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry,  2007, 64(3), 327-337.
[http://dx.doi.org/10.1001/archpsyc.64.3.327] [PMID:  17339521] 
[48] 
Dhillon, S.; Yang, L.P.; Curran, M.P. Spotlight on bupropion in major depressive disorder. CNS Drugs,  2008, 22(7), 613-617.
[http://dx.doi.org/10.2165/00023210-200822070-00006] [PMID:  18547129] 
[49] 
Simpson, D.; Plosker, G.L. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs,  2004, 18(6), 397-401.
[http://dx.doi.org/10.2165/00023210-200418060-00011] [PMID:  15089111] 
[50] 
Garnock-Jones, K.P.; Keating, G.M. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs,  2010, 24(1), 85-88.
[http://dx.doi.org/10.2165/11203670-000000000-00000] [PMID:  20030421] 
[51] 
Biederman, J.; Makris, N.; Valera, E.M.; Monuteaux, M.C.; Goldstein, J.M.; Buka, S.; Boriel, D.L.; Bandyopadhyay, S.; Kennedy, D.N.; Caviness, V.S.; Bush, G.; Aleardi, M.; Hammerness, P.; Faraone, S.V.; Seidman, L.J. Towards further understanding of the co-morbidity between attention deficit hyperactivity disorder and bipolar disorder: a MRI study of brain volumes. Psychol. Med.,  2008, 38(7), 1045-1056.
[http://dx.doi.org/10.1017/S0033291707001791] [PMID:  17935640] 
[52] 
Gardner, A.; Salmaso, D.; Varrone, A.; Sanchez-Crespo, A.; Bejerot, S.; Jacobsson, H.; Larsson, S.A.; Pagani, M. Differences at brain SPECT between depressed females with and without adult ADHD and healthy controls: etiological considerations. Behav. Brain Funct.,  2009, 5, 37.
[http://dx.doi.org/10.1186/1744-9081-5-37] [PMID:  19723308] 
[53] 
El-Mallakh, R.S. An open study of methylphenidate in bipolar depression. Bipolar Disord.,  2000, 2(1), 56-59.
[http://dx.doi.org/10.1034/j.1399-5618.2000.020108.x] [PMID:  11254021] 
[54] 
Stoll, A.L.; Pillay, S.S.; Diamond, L.; Workum, S.B.; Cole, J.O. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J. Clin. Psychiatry,  1996, 57(2), 72-76.
[PMID:  8591972] 
[55] 
Perugi, G.; Vannucchi, G.; Bedani, F.; Favaretto, E. Use of stimulants in bipolar disorder. Curr. Psychiatry Rep.,  2017, 19(1), 7.
[http://dx.doi.org/10.1007/s11920-017-0758-x] [PMID:  28144880] 
[56] 
Dorrego, M.F.; Canevaro, L.; Kuzis, G.; Sabe, L.; Starkstein, S.E. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. J. Neuropsychiatry Clin. Neurosci.,  2002, 14(3), 289-295.
[http://dx.doi.org/10.1176/jnp.14.3.289] [PMID:  12154153] 
[57] 
Barzman, D.H.; DelBello, M.P.; Adler, C.M.; Stanford, K.E.; Strakowski, S.M. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J. Child Adolesc. Psychopharmacol.,  2006, 16(6), 665-670.
[http://dx.doi.org/10.1089/cap.2006.16.665] [PMID:  17201610] 
[58] 
Atmaca, M.; Ozler, S.; Topuz, M.; Goldstein, S. Attention deficit hyperactivity disorder erroneously diagnosed and treated as bipolar disorder. J. Atten. Disord.,  2009, 13(2), 197-198.
[http://dx.doi.org/10.1177/1087054709332407] [PMID:  19380515] 
[59] 
Rydén, E.; Johansson, C.; Blennow, K.; Landén, M.; Lower, C.S.F. Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J. Neural Transm. (Vienna),  2009, 116(12), 1667-1674.
[http://dx.doi.org/10.1007/s00702-009-0300-3] [PMID:  19756368] 
[60] 
De Leo, D.; Marazziti, D. Biological prediction of suicide: the role of serotonin. Crisis,  1988, 9(2), 109-118.
[PMID:  2463897] 
[61] 
Marazziti, D.; Baroni, S.; Pirone, A.; Giannaccini, G.; Betti, L.; Schmid, L.; Vatteroni, E.; Palego, L.; Borsini, F.; Bordi, F.; Piano, I.; Gargini, C.; Castagna, M.; Catena-Dell’osso, M.; Lucacchini, A. Distribution of serotonin receptor of type 6 (5-HT6) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study. Neurochem. Res.,  2012, 37(5), 920-927.
[http://dx.doi.org/10.1007/s11064-011-0684-y] [PMID:  22278721] 
[62] 
Kent, L.; Craddock, N. Is there a relationship between attention deficit hyperactivity disorder and bipolar disorder? J. Affect. Disord.,  2003, 73(3), 211-221.
[http://dx.doi.org/10.1016/S0165-0327(02)00092-7] [PMID:  12547289] 
[63] 
Dell’Osso, L.; Carmassi, C.; Mucci, F.; Marazziti, D. Depression, serotonin and tryptophan. Curr. Pharm. Des.,  2016, 22(8), 949-954.
[http://dx.doi.org/10.2174/1381612822666151214104826] [PMID:  26654774] 
[64] 
Marazziti, D. Understanding the role of serotonin in psychiatric diseases. F1000 Res.,  2017, 6, 180.
[http://dx.doi.org/10.12688/f1000research.10094.1] [PMID:  28299200] 
[65] 
Valera, E.M.; Faraone, S.V.; Murray, K.E.; Seidman, L.J. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol. Psychiatry,  2007, 61(12), 1361-1369.
[http://dx.doi.org/10.1016/j.biopsych.2006.06.011] [PMID:  16950217] 
[66] 
Brambilla, P.; Barale, F.; Caverzasi, E.; Soares, J.C. Anatomical MRI findings in mood and anxiety disorders. Epidemiol. Psichiatr. Soc.,  2002, 11(2), 88-99.
[http://dx.doi.org/10.1017/S1121189X00005558] [PMID:  12212470] 
[67] 
Drevets, W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog. Brain Res.,,  2000, 126, 413-431.
[http://dx.doi.org/10.1016/S0079-6123(00)26027-5] [PMID:  11105660] 
[68] 
Videbech, P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr. Scand.,  1997, 96(3), 157-168.
[http://dx.doi.org/10.1111/j.1600-0447.1997.tb10146.x] [PMID:  9296545] 
[69] 
Rubia, K.; Overmeyer, S.; Taylor, E.; Brammer, M.; Williams, S.C.; Simmons, A.; Bullmore, E.T. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am. J. Psychiatry,  1999, 156(6), 891-896.
[http://dx.doi.org/10.1176/ajp.156.6.891] [PMID:  10360128] 
[70] 
Teicher, M.H.; Anderson, C.M.; Polcari, A.; Glod, C.A.; Maas, L.C.; Renshaw, P.F. Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat. Med.,  2000, 6(4), 470-473.
[http://dx.doi.org/10.1038/74737] [PMID:  10742158] 
[71] 
Bauer, J.; Werner, A.; Kohl, W.; Kugel, H.; Shushakova, A.; Pedersen, A.; Ohrmann, P. Hyperactivity and impulsivity in adult attention-deficit/hyperactivity disorder is related to glutamatergic dysfunction in the anterior cingulate cortex. World J. Biol. Psychiatry,  2018, 19(7), 538-546.
[http://dx.doi.org/10.1080/15622975.2016.1262060] [PMID:  27973969] 
[72] 
Makris, N.; Seidman, L.J.; Brown, A.; Valera, E.M.; Kaiser, J.R.; Petty, C.R.; Liang, L.; Aleardi, M.; Boriel, D.; Henderson, C.S.; Giddens, M.; Faraone, S.V.; Spencer, T.J.; Biederman, J. Further understanding of the comorbidity between attention-deficit/hyperactivity disorder and bipolar disorder in adults: an MRI study of cortical thickness. Psychiatry Res.,  2012, 202(1), 1-11.
[http://dx.doi.org/10.1016/j.pscychresns.2011.11.003] [PMID:  22640688] 
[73] 
Lopez-Larson, M.; Michael, E.S.; Terry, J.E.; Breeze, J.L.; Hodge, S.M.; Tang, L.; Kennedy, D.N.; Moore, C.M.; Makris, N.; Caviness, V.S.; Frazier, J.A. Subcortical differences among youths with attention-deficit/hyperactivity disorder compared to those with bipolar disorder with and without attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.,  2009, 19(1), 31-39.
[http://dx.doi.org/10.1089/cap.2008.041] [PMID:  19232021] 
[74] 
Lyoo, I.K.; Sung, Y.H.; Dager, S.R.; Friedman, S.D.; Lee, J.Y.; Kim, S.J.; Kim, N.; Dunner, D.L.; Renshaw, P.F. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord.,  2006, 8(1), 65-74.
[http://dx.doi.org/10.1111/j.1399-5618.2006.00284.x] [PMID:  16411982] 
[75] 
Fornito, A.; Malhi, G.S.; Lagopoulos, J.; Ivanovski, B.; Wood, S.J.; Saling, M.M.; Pantelis, C.; Yücel, M. Anatomical abnormalities of the anterior cingulate and paracingulate cortex in patients with bipolar I disorder. Psychiatry Res.,  2008, 162(2), 123-132.
[http://dx.doi.org/10.1016/j.pscychresns.2007.06.004] [PMID:  18207705] 
[76] 
Rimol, L.M.; Panizzon, M.S.; Fennema-Notestine, C.; Eyler, L.T.; Fischl, B.; Franz, C.E.; Hagler, D.J.; Lyons, M.J.; Neale, M.C.; Pacheco, J.; Perry, M.E.; Schmitt, J.E.; Grant, M.D.; Seidman, L.J.; Thermenos, H.W.; Tsuang, M.T.; Eisen, S.A.; Kremen, W.S.; Dale, A.M. Cortical thickness is influenced by regionally specific genetic factors. Biol. Psychiatry,  2010, 67(5), 493-499.
[http://dx.doi.org/10.1016/j.biopsych.2009.09.032] [PMID:  19963208] 
[77] 
Sowell, E.R.; Thompson, P.M.; Welcome, S.E.; Henkenius, A.L.; Toga, A.W.; Peterson, B.S. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet,  2003, 362(9397), 1699-1707.
[http://dx.doi.org/10.1016/S0140-6736(03)14842-8] [PMID:  14643117] 
[78] 
Makris, N.; Biederman, J.; Valera, E.M.; Bush, G.; Kaiser, J.; Kennedy, D.N.; Caviness, V.S.; Faraone, S.V.; Seidman, L.J. Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. Cereb. Cortex,  2007, 17(6), 1364-1375.
[http://dx.doi.org/10.1093/cercor/bhl047] [PMID:  16920883] 
[79] 
Shaw, P.; Eckstrand, K.; Sharp, W.; Blumenthal, J.; Lerch, J.P.; Greenstein, D.; Clasen, L.; Evans, A.; Giedd, J.; Rapoport, J.L. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc. Natl. Acad. Sci. USA,  2007, 104(49), 19649-19654.
[http://dx.doi.org/10.1073/pnas.0707741104] [PMID:  18024590] 
[80] 
Batty, M.J.; Liddle, E.B.; Pitiot, A.; Toro, R.; Groom, M.J.; Scerif, G.; Liotti, M.; Liddle, P.F.; Paus, T.; Hollis, C. Cortical gray matter in attention-deficit/hyperactivity disorder: a structural magnetic resonance imaging study. J. Am. Acad. Child Adolesc. Psychiatry,  2010, 49(3), 229-238.
[http://dx.doi.org/10.1097/00004583-201003000-00006] [PMID:  20410712] 
[81] 
Almeida, L.G.; Ricardo-Garcell, J.; Prado, H.; Barajas, L.; Fernández-Bouzas, A.; Avila, D.; Martínez, R.B. Reduced right frontal cortical thickness in children, adolescents and adults with ADHD and its correlation to clinical variables: a cross-sectional study. J. Psychiatr. Res.,  2010, 44(16), 1214-1223.
[http://dx.doi.org/10.1016/j.jpsychires.2010.04.026] [PMID:  20510424] 
[82] 
Mayberg, H. Mapping mood: an evolving emphasis on frontal-limbic interactions. Principles of frontal lobe function; Stuss, D.T; Knight, R.T., Ed.; Oxford University Press: New York, 2002, pp. 376-391.
[http://dx.doi.org/10.1093/acprof:oso/9780195134971.003.0024] 
[83] 
Castellanos, F.X.; Giedd, J.N.; Eckburg, P.; Marsh, W.L.; Vaituzis, A.C.; Kaysen, D.; Hamburger, S.D.; Rapoport, J.L. Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder. Am. J. Psychiatry,  1994, 151(12), 1791-1796.
[http://dx.doi.org/10.1176/ajp.151.12.1791] [PMID:  7977887] 
[84] 
Castellanos, F.X.; Lee, P.P.; Sharp, W.; Jeffries, N.O.; Greenstein, D.K.; Clasen, L.S.; Blumenthal, J.D.; James, R.S.; Ebens, C.L.; Walter, J.M.; Zijdenbos, A.; Evans, A.C.; Giedd, J.N.; Rapoport, J.L. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA,  2002, 288(14), 1740-1748.
[http://dx.doi.org/10.1001/jama.288.14.1740] [PMID:  12365958] 
[85] 
DelBello, M.P.; Zimmerman, M.E.; Mills, N.P.; Getz, G.E.; Strakowski, S.M. Magnetic resonance imaging analysis of amygdala and other subcortical brain regions in adolescents with bipolar disorder. Bipolar Disord.,  2004, 6(1), 43-52.
[http://dx.doi.org/10.1046/j.1399-5618.2003.00087.x] [PMID:  14996140] 
[86] 
Aylward, E.H.; Reiss, A.L.; Reader, M.J.; Singer, H.S.; Brown, J.E.; Denckla, M.B. Basal ganglia volumes in children with attention-deficit hyperactivity disorder. J. Child Neurol.,  1996, 11(2), 112-115.
[http://dx.doi.org/10.1177/088307389601100210] [PMID:  8881987] 
[87] 
Filipek, P.A.; Semrud-Clikeman, M.; Steingard, R.J.; Renshaw, P.F.; Kennedy, D.N.; Biederman, J. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology,  1997, 48(3), 589-601.
[http://dx.doi.org/10.1212/WNL.48.3.589] [PMID:  9065532] 
[88] 
Overmeyer, S.; Bullmore, E.T.; Suckling, J.; Simmons, A.; Williams, S.C.; Santosh, P.J.; Taylor, E. Distributed grey and white matter deficits in hyperkinetic disorder: MRI evidence for anatomical abnormality in an attentional network. Psychol. Med.,  2001, 31(8), 1425-1435.
[http://dx.doi.org/10.1017/S0033291701004706] [PMID:  11722157] 
[89] 
McAlonan, G.M.; Cheung, V.; Cheung, C.; Chua, S.E.; Murphy, D.G.; Suckling, J.; Tai, K.S.; Yip, L.K.; Leung, P.; Ho, T.P. Mapping brain structure in attention deficit-hyperactivity disorder: a voxel-based MRI study of regional grey and white matter volume. Psychiatry Res.,  2007, 154(2), 171-180.
[http://dx.doi.org/10.1016/j.pscychresns.2006.09.006] [PMID:  17291727] 
[90] 
Wang, J.; Jiang, T.; Cao, Q.; Wang, Y. Characterizing anatomic differences in boys with attention-deficit/hyperactivity disorder with the use of deformation-based morphometry. AJNR Am. J. Neuroradiol.,  2007, 28(3), 543-547.
[PMID:  17353333] 
[91] 
Wellington, T.M.; Semrud-Clikeman, M.; Gregory, A.L.; Murphy, J.M.; Lancaster, J.L. Magnetic resonance imaging volumetric analysis of the putamen in children with ADHD: combined type versus control. J. Atten. Disord.,  2006, 10(2), 171-180.
[http://dx.doi.org/10.1177/1087054705284242] [PMID:  17085627] 
[92] 
Wilke, M.; Kowatch, R.A.; DelBello, M.P.; Mills, N.P.; Holland, S.K. Voxel-based morphometry in adolescents with bipolar disorder: first results. Psychiatry Res.,  2004, 131(1), 57-69.
[http://dx.doi.org/10.1016/j.pscychresns.2004.01.004] [PMID:  15246455] 
[93] 
Buckner, R.L.; Andrews-Hanna, J.R.; Schacter, D.L. The brain’s default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci.,  2008, 1124, 1-38.
[http://dx.doi.org/10.1196/annals.1440.011] [PMID:  18400922] 
[94] 
Raichle, M.E.; MacLeod, A.M.; Snyder, A.Z.; Powers, W.J.; Gusnard, D.A.; Shulman, G.L. A default mode of brain function. Proc. Natl. Acad. Sci. USA,  2001, 98(2), 676-682.
[http://dx.doi.org/10.1073/pnas.98.2.676] [PMID:  11209064] 
[95] 
Raichle, M.E. The brain’s default mode network. Annu. Rev. Neurosci.,  2015, 38, 433-447.
[http://dx.doi.org/10.1146/annurev-neuro-071013-014030] [PMID:  25938726] 
[96] 
Broyd, S.J.; Demanuele, C.; Debener, S.; Helps, S.K.; James, C.J.; Sonuga-Barke, E.J. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci. Biobehav. Rev.,  2009, 33(3), 279-296.
[http://dx.doi.org/10.1016/j.neubiorev.2008.09.002] [PMID:  18824195] 
[97] 
Buckner, R.L. The serendipitous discovery of the brain’s default network. Neuroimage,  2012, 62(2), 1137-1145.
[http://dx.doi.org/10.1016/j.neuroimage.2011.10.035] [PMID:  22037421] 
[98] 
Cha, D.S.; De Michele, F.; Soczynska, J.K.; Woldeyohannes, H.O.; Kaidanovich-Beilin, O.; Carvalho, A.F.; Malhi, G.S.; Patel, H.; Sim, K.; Brietzke, E.; Mansur, R.; Dunlop, K.A.; Alsuwaidan, M.; Baskaran, A.; Fagiolini, A.; Reznikov, R.; Kudlow, P.A.; McIntyre, R.S. The putative impact of metabolic health on default mode network activity and functional connectivity in neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets,  2014, 13(10), 1750-1758.
[http://dx.doi.org/10.2174/1871527313666141130205024] [PMID:  25470392] 
[99] 
Sala-Llonch, R.; Bartrés-Faz, D.; Junqué, C. Reorganization of brain networks in aging: a review of functional connectivity studies. Front. Psychol.,  2015, 6, 663.
[http://dx.doi.org/10.3389/fpsyg.2015.00663] [PMID:  26052298] 
[100] 
Franzen, J.D.; Heinrichs-Graham, E.; White, M.L.; Wetzel, M.W.; Knott, N.L.; Wilson, T.W. Atypical coupling between posterior regions of the default mode network in attention-deficit/hyperactivity disorder: a pharmaco-magnetoencephalography study. J. Psychiatry Neurosci.,  2013, 38(5), 333-340.
[http://dx.doi.org/10.1503/jpn.120054] [PMID:  23611175] 
[101] 
Haneef, Z.; Lenartowicz, A.; Yeh, H.J.; Engel, J., Jr; Stern, J.M. Network analysis of the default mode network using functional connectivity MRI in temporal lobe epilepsy. J. Vis. Exp., 2014, (90)e51442
[http://dx.doi.org/10.3791/51442] [PMID:  25146174] 
[102] 
Lopes, R.; Moeller, F.; Besson, P.; Ogez, F.; Szurhaj, W.; Leclerc, X.; Siniatchkin, M.; Chipaux, M.; Derambure, P.; Tyvaert, L. Study on the relationships between intrinsic functional connectivity of the default mode network and transient epileptic activity. Front. Neurol.,  2014, 5, 201.
[http://dx.doi.org/10.3389/fneur.2014.00201] [PMID:  25346721] 
[103] 
Shi, H.; Wang, X.; Yi, J.; Zhu, X.; Zhang, X.; Yang, J.; Yao, S. Default mode network alterations during implicit emotional faces processing in first-episode, treatment-naive major depression patients. Front. Psychol.,  2015, 6, 1198.
[http://dx.doi.org/10.3389/fpsyg.2015.01198] [PMID:  26322003] 
[104] 
Dennis, E.L.; Thompson, P.M. Functional brain connectivity using fMRI in aging and Alzheimer’s disease. Neuropsychol. Rev.,  2014, 24(1), 49-62.
[http://dx.doi.org/10.1007/s11065-014-9249-6] [PMID:  24562737] 
[105] 
Greicius, M.D.; Krasnow, B.; Reiss, A.L.; Menon, V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc. Natl. Acad. Sci. USA,  2003, 100(1), 253-258.
[http://dx.doi.org/10.1073/pnas.0135058100] [PMID:  12506194] 
[106] 
Diolaiuti, F.; Banfi, T.; Santarcangelo, E.L. Hypnotizability and the peripersonal space. Int. J. Clin. Exp. Hypn.,  2017, 65(4), 466-478.
[http://dx.doi.org/10.1080/00207144.2017.1348868] [PMID:  28836923] 
[107] 
Castellanos, F.X.; Margulies, D.S.; Kelly, C.; Uddin, L.Q.; Ghaffari, M.; Kirsch, A.; Shaw, D.; Shehzad, Z.; Di Martino, A.; Biswal, B.; Sonuga-Barke, E.J.; Rotrosen, J.; Adler, L.A.; Milham, M.P. Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry,  2008, 63(3), 332-337.
[http://dx.doi.org/10.1016/j.biopsych.2007.06.025] [PMID:  17888409] 
[108] 
Uddin, L.Q.; Kelly, A.M.; Biswal, B.B.; Margulies, D.S.; Shehzad, Z.; Shaw, D.; Ghaffari, M.; Rotrosen, J.; Adler, L.A.; Castellanos, F.X.; Milham, M.P. Network homogeneity reveals decreased integrity of default-mode network in ADHD. J. Neurosci. Methods,  2008, 169(1), 249-254.
[http://dx.doi.org/10.1016/j.jneumeth.2007.11.031] [PMID:  18190970] 
[109] 
Maddock, R.J. The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. Trends Neurosci.,  1999, 22(7), 310-316.
[http://dx.doi.org/10.1016/S0166-2236(98)01374-5] [PMID:  10370255] 
[110] 
Gusnard, D.A.; Akbudak, E.; Shulman, G.L.; Raichle, M.E. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc. Natl. Acad. Sci. USA,  2001, 98(7), 4259-4264.
[http://dx.doi.org/10.1073/pnas.071043098] [PMID:  11259662] 
[111] 
Simpson, J.R., Jr; Snyder, A.Z.; Gusnard, D.A.; Raichle, M.E. Emotion-induced changes in human medial prefrontal cortex: I. During cognitive task performance. Proc. Natl. Acad. Sci. USA,  2001, 98(2), 683-687.
[http://dx.doi.org/10.1073/pnas.98.2.683] [PMID:  11209065] 
[112] 
Posner, J.; Park, C.; Wang, Z. Connecting the dots: a review of resting connectivity MRI studies in attention-deficit/hyperactivity disorder. Neuropsychol. Rev.,  2014, 24(1), 3-15.
[http://dx.doi.org/10.1007/s11065-014-9251-z] [PMID:  24496902] 
[113] 
Mohan, A.; Roberto, A.J.; Mohan, A.; Lorenzo, A.; Jones, K.; Carney, M.J.; Liogier-Weyback, L.; Hwang, S.; Lapidus, K.A. The significance of the Default Mode Network (DMN) in neurological and neuropsychiatric disorders: a review. Yale J. Biol. Med.,  2016, 89(1), 49-57.
[PMID:  27505016] 
[114] 
van Rooij, D.; Hartman, C.A.; Mennes, M.; Oosterlaan, J.; Franke, B.; Rommelse, N.; Heslenfeld, D.; Faraone, S.V.; Buitelaar, J.K.; Hoekstra, P.J. Altered neural connectivity during response inhibition in adolescents with attention-deficit/hyperactivity disorder and their unaffected siblings. Neuroimage Clin.,  2015, 7, 325-335.
[http://dx.doi.org/10.1016/j.nicl.2015.01.004] [PMID:  25610797] 
[115] 
Liddle, E.B.; Hollis, C.; Batty, M.J.; Groom, M.J.; Totman, J.J.; Liotti, M.; Scerif, G.; Liddle, P.F. Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. J. Child Psychol. Psychiatry,  2011, 52(7), 761-771.
[http://dx.doi.org/10.1111/j.1469-7610.2010.02333.x] [PMID:  21073458] 
[116] 
Cole, M.W.; Schneider, W. The cognitive control network: Integrated cortical regions with dissociable functions. Neuroimage,  2007, 37(1), 343-360.
[http://dx.doi.org/10.1016/j.neuroimage.2007.03.071] [PMID:  17553704] 
[117] 
Sun, L.; Cao, Q.; Long, X.; Sui, M.; Cao, X.; Zhu, C.; Zuo, X.; An, L.; Song, Y.; Zang, Y.; Wang, Y. Abnormal functional connectivity between the anterior cingulate and the default mode network in drug-naïve boys with attention deficit hyperactivity disorder. Psychiatry Res.,  2012, 201(2), 120-127.
[http://dx.doi.org/10.1016/j.pscychresns.2011.07.001] [PMID:  22424873] 
[118] 
Sato, J.R.; Hoexter, M.Q.; Castellanos, X.F.; Rohde, L.A. Abnormal brain connectivity patterns in adults with ADHD: a coherence study. PLoS One,  2012, 7(9)e45671
[http://dx.doi.org/10.1371/journal.pone.0045671] [PMID:  23049834] 
[119] 
Hoekzema, E.; Carmona, S.; Ramos-Quiroga, J.A.; Richarte Fernández, V.; Bosch, R.; Soliva, J.C.; Rovira, M.; Bulbena, A.; Tobeña, A.; Casas, M.; Vilarroya, O. An independent components and functional connectivity analysis of resting state fMRI data points to neural network dysregulation in adult ADHD. Hum. Brain Mapp.,  2014, 35(4), 1261-1272.
[http://dx.doi.org/10.1002/hbm.22250] [PMID:  23417778] 
[120] 
Zhu, X.; Wang, X.; Xiao, J.; Liao, J.; Zhong, M.; Wang, W.; Yao, S. Evidence of a dissociation pattern in resting-state default mode network connectivity in first-episode, treatment-naive major depression patients. Biol. Psychiatry,  2012, 71(7), 611-617.
[http://dx.doi.org/10.1016/j.biopsych.2011.10.035] [PMID:  22177602] 
[121] 
Guo, W.; Liu, F.; Xue, Z.; Gao, K.; Liu, Z.; Xiao, C.; Chen, H.; Zhao, J. Decreased interhemispheric coordination in treatment-resistant depression: a resting-state fMRI study. PLoS One,  2013, 8(8)e71368
[http://dx.doi.org/10.1371/journal.pone.0071368] [PMID:  23936504] 
[122] 
Qin, J.; Shen, H.; Zeng, L.L.; Jiang, W.; Liu, L.; Hu, D. Predicting clinical responses in major depression using intrinsic functional connectivity. Neuroreport,  2015, 26(12), 675-680.
[http://dx.doi.org/10.1097/WNR.0000000000000407] [PMID:  26164454] 
[123] 
Vargas, C.; López-Jaramillo, C.; Vieta, E. A systematic literature review of resting state network--functional MRI in bipolar disorder. J. Affect. Disord.,  2013, 150(3), 727-735.
[http://dx.doi.org/10.1016/j.jad.2013.05.083] [PMID:  23830141] 
[124] 
Dell’Osso, B.; Dobrea, C.; Cremaschi, L.; Arici, C.; Altamura, A.C. Wake-promoting pharmacotherapy for psychiatric disorders. Curr. Psychiatry Rep.,  2014, 16(12), 524.
[http://dx.doi.org/10.1007/s11920-014-0524-2] [PMID:  25312027] 
[125] 
Markowitz, J.S.; Straughn, A.B.; Patrick, K.S. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy,  2003, 23(10), 1281-1299.
[http://dx.doi.org/10.1592/phco.23.12.1281.32697] [PMID:  14594346] 
[126] 
Panizzon, L. The preparation of pyridyl- and piperidyl-arylacetonitriles and some transformation products (Part Ia). Helv. Chim. Acta,  1944, 27(1), 1748-1756.
[http://dx.doi.org/10.1002/hlca.194402701222] 
[127] 
Arnsten, A.F.; Li, B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry,  2005, 57(11), 1377-1384.
[http://dx.doi.org/10.1016/j.biopsych.2004.08.019] [PMID:  15950011] 
[128] 
Markowitz, J.S.; Patrick, K.S. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J. Clin. Psychopharmacol.,  2008, 28(3)(Suppl. 2), S54-S61.
[http://dx.doi.org/10.1097/JCP.0b013e3181733560] [PMID:  18480678] 
[129] 
Williard, R.L.; Middaugh, L.D.; Zhu, H.J.; Patrick, K.S. Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav. Pharmacol.,  2007, 18(1), 39-51.
[http://dx.doi.org/10.1097/FBP.0b013e3280143226] [PMID:  17218796] 
[130] 
Markowitz, J.S.; DeVane, C.L.; Pestreich, L.K.; Patrick, K.S.; Muniz, R. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J. Child Adolesc. Psychopharmacol.,  2006, 16(6), 687-698.
[http://dx.doi.org/10.1089/cap.2006.16.687] [PMID:  17201613] 
[131] 
Canadian Attention Deficit Hyperactivity Resource Alliance Assessment and treatment of ADHD uncomplicated- adults. Available at: https://caddra.ca/pdfs/caddraGuidelines2011Chapter07.pdf. [Accessed: December 8th, 2017].
[132] 
Chan, Y.P.; Swanson, J.M.; Soldin, S.S.; Thiessen, J.J.; Macleod, S.M.; Logan, W. Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics,  1983, 72(1), 56-59.
[PMID:  6866592] 
[133] 
Lehmann, D.F.; Wojnowicz, S. The evergreening of biopharmaceuticals: Time to defoliate. J. Clin. Pharmacol.,  2016, 56(4), 383-389.
[http://dx.doi.org/10.1002/jcph.642] [PMID:  26388527] 
[134] 
Markowitz, J.S.; DeVane, C.L.; Ramamoorthy, S.; Zhu, H.J. The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Pharmazie,  2009, 64(2), 123-125.
[PMID:  19322953] 
[135] 
Heal, D.J.; Pierce, D.M. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs,  2006, 20(9), 713-738.
[http://dx.doi.org/10.2165/00023210-200620090-00002] [PMID:  16953648] 
[136] 
Iversen, L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br. J. Pharmacol.,  2006, 147(Suppl. 1), S82-S88.
[http://dx.doi.org/10.1038/sj.bjp.0706428] [PMID:  16402124] 
[137] 
Volkow, N.D.; Fowler, J.S.; Wang, G.; Ding, Y.; Gatley, S.J. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord.,  2002, 6(Suppl. 1), S31-S43.
[http://dx.doi.org/10.1177/070674370200601S05] [PMID:  12685517] 
[138] 
Hodgkins, P.; Shaw, M.; Coghill, D.; Hechtman, L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur. Child Adolesc. Psychiatry,  2012, 21(9), 477-492.
[http://dx.doi.org/10.1007/s00787-012-0286-5] [PMID:  22763750] 
[139] 
Berridge, C.W.; Devilbiss, D.M.; Andrzejewski, M.E.; Arnsten, A.F.; Kelley, A.E.; Schmeichel, B.; Hamilton, C.; Spencer, R.C. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol. Psychiatry,  2006, 60(10), 1111-1120.
[http://dx.doi.org/10.1016/j.biopsych.2006.04.022] [PMID:  16806100] 
[140] 
Stahl, S.M. Stahl’s essential psychopharmacology: prescriber’s guide, 5th ed; Cambridge University Press: Cambridge, United Kingdom, 2017. 
[141] 
Peterson, K.; McDonagh, M.S.; Fu, R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl.),  2008, 197(1), 1-11.
[http://dx.doi.org/10.1007/s00213-007-0996-4] [PMID:  18026719] 
[142] 
 National Institute for Health and Care Excellence (NICE).
Attention deficit hyperactivity disorder: diagnosis and management.
Available at: https://www.nice.org.uk/guidance/cg72. [Accessed: December 8th, 2017].
[143] 
Findling, R.L.; Short, E.J.; McNamara, N.K.; Demeter, C.A.; Stansbrey, R.J.; Gracious, B.L.; Whipkey, R.; Manos, M.J.; Calabrese, J.R. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry,  2007, 46(11), 1445-1453.
[http://dx.doi.org/10.1097/chi.0b013e31814b8d3b] [PMID:  18049294] 
[144] 
Zeni, C.P.; Tramontina, S.; Ketzer, C.R.; Pheula, G.F.; Rohde, L.A. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J. Child Adolesc. Psychopharmacol.,  2009, 19(5), 553-561.
[http://dx.doi.org/10.1089/cap.2009.0037] [PMID:  19877980] 
[145] 
Ross, R.G. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am. J. Psychiatry,  2006, 163(7), 1149-1152.
[http://dx.doi.org/10.1176/ajp.2006.163.7.1149] [PMID:  16816217] 
[146] 
Kraemer, M.; Uekermann, J.; Wiltfang, J.; Kis, B. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin. Neuropharmacol.,  2010, 33(4), 204-206.
[http://dx.doi.org/10.1097/WNF.0b013e3181e29174] [PMID:  20571380] 
[147] 
Manor, I.; Rozen, S.; Zemishlani, Z.; Weizman, A.; Zalsman, G. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations. Clin. Neuropharmacol.,  2011, 34(4), 148-154.
[http://dx.doi.org/10.1097/WNF.0b013e3182206dc1] [PMID:  21738027] 
[148] 
Torgersen, T.; Gjervan, B.; Lensing, M.B.; Rasmussen, K. Optimal management of ADHD in older adults. Neuropsychiatr. Dis. Treat.,  2016, 12, 79-87.
[http://dx.doi.org/10.2147/NDT.S59271] [PMID:  26811680] 
[149] 
Hardy, S.E. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am. J. Geriatr. Pharmacother.,  2009, 7(1), 34-59.
[http://dx.doi.org/10.1016/j.amjopharm.2009.02.006] [PMID:  19281939] 
[150] 
Huss, M.; Ginsberg, Y.; Tvedten, T.; Arngrim, T.; Philipsen, A.; Carter, K.; Chen, C.W.; Kumar, V. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv. Ther.,  2014, 31(1), 44-65.
[http://dx.doi.org/10.1007/s12325-013-0085-5] [PMID:  24371021] 
[151] 
Kurlan, R. Tourette’s syndrome: are stimulants safe? Curr. Neurol. Neurosci. Rep.,  2003, 3(4), 285-288.
[http://dx.doi.org/10.1007/s11910-003-0004-2] [PMID:  12930697] 
[152] 
Türkoğlu, S. Serotonin syndrome with sertraline and methylphenidate in an adolescent. Clin. Neuropharmacol.,  2015, 38(2), 65-66.
[http://dx.doi.org/10.1097/WNF.0000000000000075] [PMID:  25768857] 
[153] 
Ishii, M.; Tatsuzawa, Y.; Yoshino, A.; Nomura, S. Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry Clin. Neurosci.,  2008, 62(2), 246.
[http://dx.doi.org/10.1111/j.1440-1819.2008.01767.x] [PMID:  18412855] 
[154] 
Bodner, R.A.; Lynch, T.; Lewis, L.; Kahn, D. Serotonin syndrome. Neurology,  1995, 45(2), 219-223.
[http://dx.doi.org/10.1212/WNL.45.2.219] [PMID:  7854515] 
[155] 
Roberts, S.M.; DeMott, R.P.; James, R.C. Adrenergic modulation of hepatotoxicity. Drug Metab. Rev.,  1997, 29(1-2), 329-353.
[http://dx.doi.org/10.3109/03602539709037587] [PMID:  9187524] 
[156] 
Haervig, K.B.; Mortensen, L.H.; Hansen, A.V.; Strandberg-Larsen, K. Use of ADHD medication during pregnancy from 1999 to 2010: A Danish register-based study. Pharmacoepidemiol. Drug Saf.,  2014, 23(5), 526-533.
[http://dx.doi.org/10.1002/pds.3600] [PMID:  24590619] 
[157] 
Heal, D.J.; Smith, S.L.; Gosden, J.; Nutt, D.J. Amphetamine, past and present--a pharmacological and clinical perspective. J. Psychopharmacol. (Oxford),  2013, 27(6), 479-496.
[http://dx.doi.org/10.1177/0269881113482532] [PMID:  23539642] 
[158] 
Goodman, L.S.; Gilman, A.G.; Brunton, L.L.; Chabner, B.A.; Knollmann Björn, C. Goodman & Gilmans the pharmacological basis of therapeutics, 12th ed; McGraw-Hill Medical: New York, 2011. 
[159] 
Foye, W.O.; Lemke, T.L.; Williams, D.A. Principles of medicinal chemistry; Williams & Wilkins: Baltimore, 1996. 
[160] 
Adderal, X.R. Prescribing information., Available at:. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf [Accessed: December 8th, 2017]
[161] 
Miller, G.M. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurochem.,  2011, 116(2), 164-176.
[http://dx.doi.org/10.1111/j.1471-4159.2010.07109.x] [PMID:  21073468] 
[162] 
Bidwell, L.C.; McClernon, F.J.; Kollins, S.H. Cognitive enhancers for the treatment of ADHD. Pharmacol. Biochem. Behav.,  2011, 99(2), 262-274.
[http://dx.doi.org/10.1016/j.pbb.2011.05.002] [PMID:  21596055] 
[163] 
Broadley, K.J. The vascular effects of trace amines and amphetamines. Pharmacol. Ther.,  2010, 125(3), 363-375.
[http://dx.doi.org/10.1016/j.pharmthera.2009.11.005] [PMID:  19948186] 
[164] 
Underhill, S.M.; Wheeler, D.S.; Li, M.; Watts, S.D.; Ingram, S.L.; Amara, S.G. Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons. Neuron,  2014, 83(2), 404-416.
[http://dx.doi.org/10.1016/j.neuron.2014.05.043] [PMID:  25033183] 
[165] 
Spencer, R.C.; Devilbiss, D.M.; Berridge, C.W. The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol. Psychiatry,  2015, 77(11), 940-950.
[http://dx.doi.org/10.1016/j.biopsych.2014.09.013] [PMID:  25499957] 
[166] 
Ilieva, I.P.; Hook, C.J.; Farah, M.J. Prescription stimulants’ effects on healthy inhibitory control, working memory, and episodic memory: A meta-analysis. J. Cogn. Neurosci.,  2015, 27(6), 1069-1089.
[http://dx.doi.org/10.1162/jocn_a_00776] [PMID:  25591060] 
[167] 
Bagot, K.S.; Kaminer, Y. Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction,  2014, 109(4), 547-557.
[http://dx.doi.org/10.1111/add.12460] [PMID:  24749160] 
[168] 
Wood, S.; Sage, J.R.; Shuman, T.; Anagnostaras, S.G. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol. Rev.,  2013, 66(1), 193-221.
[http://dx.doi.org/10.1124/pr.112.007054] [PMID:  24344115] 
[169] 
Philpot, K.; Smith, Y. CART peptide and the mesolimbic dopamine system. Peptides,  2006, 27(8), 1987-1992.
[http://dx.doi.org/10.1016/j.peptides.2005.11.028] [PMID:  16759749] 
[170] 
Ashok, A.H.; Mizuno, Y.; Volkow, N.D.; Howes, O.D. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry,  2017, 74(5), 511-519.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.0135] [PMID:  28297025] 
[171] 
Scheffer, R.E.; Kowatch, R.A.; Carmody, T.; Rush, A.J. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am. J. Psychiatry,  2005, 162(1), 58-64.
[http://dx.doi.org/10.1176/appi.ajp.162.1.58] [PMID:  15625202] 
[172] 
Parker, G.; Brotchie, H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr. Scand.,  2010, 121(4), 308-314.
[http://dx.doi.org/10.1111/j.1600-0447.2009.01434.x] [PMID:  19594481] 
[173] 
Carlson, P.J.; Merlock, M.C.; Suppes, T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord.,  2004, 6(5), 416-420.
[http://dx.doi.org/10.1111/j.1399-5618.2004.00132.x] [PMID:  15383134] 
[174] 
Hart, H.; Radua, J.; Nakao, T.; Mataix-Cols, D.; Rubia, K. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry,  2013, 70(2), 185-198.
[http://dx.doi.org/10.1001/jamapsychiatry.2013.277] [PMID:  23247506] 
[175] 
Spencer, T.J.; Brown, A.; Seidman, L.J.; Valera, E.M.; Makris, N.; Lomedico, A.; Faraone, S.V.; Biederman, J. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J. Clin. Psychiatry,  2013, 74(9), 902-917.
[http://dx.doi.org/10.4088/JCP.12r08287] [PMID:  24107764] 
[176] 
Frodl, T.; Skokauskas, N. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr. Scand.,  2012, 125(2), 114-126.
[http://dx.doi.org/10.1111/j.1600-0447.2011.01786.x] [PMID:  22118249] 
[177] 
Arnold, L.E.; Hodgkins, P.; Caci, H.; Kahle, J.; Young, S. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One,  2015, 10(2)e0116407
[http://dx.doi.org/10.1371/journal.pone.0116407] [PMID:  25714373] 
[178] 
Kessler, S. Drug therapy in attention-deficit hyperactivity disorder. South. Med. J.,  1996, 89(1), 33-38.
[http://dx.doi.org/10.1097/00007611-199601000-00005] [PMID:  8545689] 
[179] 
Westover, A.N.; Halm, E.A. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC Cardiovasc. Disord.,  2012, 12, 41.
[http://dx.doi.org/10.1186/1471-2261-12-41] [PMID:  22682429] 
[180] 
Thomas, S.J.; Shin, M.; McInnis, M.G.; Bostwick, J.R. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy,  2015, 35(4), 433-449.
[http://dx.doi.org/10.1002/phar.1576] [PMID:  25884531] 
[181] 
Israel, J.A. Combining stimulants and monoamine oxidase inhibitors: A reexamination of the literature and a report of a new treatment combination. Prim. Care Companion CNS Disord.,  2015, 17(6)
[http://dx.doi.org/10.4088/PCC.15br01836] [PMID:  27057401] 
[182] 
Feinberg, S.S. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J. Clin. Psychiatry,  2004, 65(11), 1520-1524.
[http://dx.doi.org/10.4088/JCP.v65n1113] [PMID:  15554766] 
[183] 
Andrade, C. Risk of major congenital malformations associated with the use of methylphenidate or amphetamines in pregnancy. J. Clin. Psychiatry,  2018, 79(1), 18f12108..
[http://dx.doi.org/10.4088/JCP.18f12108] [PMID:  29370484] 
[184] 
Bartu, A.; Dusci, L.J.; Ilett, K.F. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br. J. Clin. Pharmacol.,  2009, 67(4), 455-459.
[http://dx.doi.org/10.1111/j.1365-2125.2009.03366.x] [PMID:  19371319] 
[185] 
Ghuman, J.K.; Hutchison, S.L. Atomoxetine is a second-line medication treatment option for ADHD. Evid. Based Ment. Health,  2014, 17(4), 108.
[http://dx.doi.org/10.1136/eb-2014-101805] [PMID:  25165169] 
[186] 
Jasinski, D.R.; Faries, D.E.; Moore, R.J.; Schuh, L.M.; Allen, A.J. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend.,  2008, 95(1-2), 140-146.
[http://dx.doi.org/10.1016/j.drugalcdep.2008.01.008] [PMID:  18328639] 
[187] 
Michelson, D.; Adler, L.; Spencer, T.; Reimherr, F.W.; West, S.A.; Allen, A.J.; Kelsey, D.; Wernicke, J.; Dietrich, A.; Milton, D. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry,  2003, 53(2), 112-120.
[http://dx.doi.org/10.1016/S0006-3223(02)01671-2] [PMID:  12547466] 
[188] 
Wilens, T.E.; Adler, L.A.; Weiss, M.D.; Michelson, D.; Ramsey, J.L.; Moore, R.J.; Renard, D.; Brady, K.T.; Trzepacz, P.T.; Schuh, L.M.; Ahrbecker, L.M.; Levine, L.R.; Atomoxetine, A.S.U.D.S.G. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend.,  2008, 96(1-2), 145-154.
[http://dx.doi.org/10.1016/j.drugalcdep.2008.02.009] [PMID:  18403134] 
[189] 
Taylor, D.; Kapur, S.; Paton, C.; Maudsley, H. The Maudsley prescribing guidelines in psychiatry, 12th ed; Wiley-Blackwell: Chichester, 2012. 
[190] 
Sauer, J.M.; Ring, B.J.; Witcher, J.W. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet.,  2005, 44(6), 571-590.
[http://dx.doi.org/10.2165/00003088-200544060-00002] [PMID:  15910008] 
[191] 
Brown, J.T.; Bishop, J.R. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics,  2015, 16(13), 1513-1520.
[http://dx.doi.org/10.2217/PGS.15.93] [PMID:  26314574] 
[192] 
Koda, K.; Ago, Y.; Cong, Y.; Kita, Y.; Takuma, K.; Matsuda, T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J. Neurochem.,  2010, 114(1), 259-270.
[http://dx.doi.org/10.1111/j.1471-4159.2010.06750.x] [PMID:  20403082] 
[193] 
Chang, K.; Nayar, D.; Howe, M.; Rana, M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J. Child Adolesc. Psychopharmacol.,  2009, 19(5), 547-551.
[http://dx.doi.org/10.1089/cap.2009.0030] [PMID:  19877979] 
[194] 
Castaneda, R.; Levy, R.; Hazzi, C.; Ross, S.; Roman, W.; Hamid, H. Treating adult attention deficit hyperactivity disorder in hospitalized psychiatric patients. Gen. Hosp. Psychiatry,  2008, 30(6), 572-577.
[http://dx.doi.org/10.1016/j.genhosppsych.2008.08.006] [PMID:  19061685] 
[195] 
Steinberg, S.; Chouinard, G. A case of mania associated with tomoxetine. Am. J. Psychiatry,  1985, 142(12), 1517-1518.
[http://dx.doi.org/10.1176/ajp.142.12.1517] [PMID:  4073327] 
[196] 
Kumar, V.; Varambally, S. Atomoxetine induced hypomania in a patient with bipolar disorder and adult attention deficit hyperactivity disorder. Indian J. Psychol. Med.,  2017, 39(1), 89-91.
[http://dx.doi.org/10.4103/0253-7176.198954] [PMID:  28250566] 
[197] 
Henderson, T.A.; Hartman, K. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics,  2004, 114(3), 895-896.
[http://dx.doi.org/10.1542/peds.2004-1140] [PMID:  15342872] 
[198] 
Lenzi, F.; Cortese, S.; Harris, J.; Masi, G. Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis. Neurosci. Biobehav. Rev.,  2018, 84, 359-367.
[http://dx.doi.org/10.1016/j.neubiorev.2017.08.010] [PMID:  28837827] 
[199] 
Wilens, T.E.; Adler, L.A.; Tanaka, Y.; Xiao, F.; D’Souza, D.N.; Gutkin, S.W.; Upadhyaya, H.P. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr. Med. Res. Opin.,  2011, 27(12), 2309-2320.
[http://dx.doi.org/10.1185/03007995.2011.628648] [PMID:  22029549] 
[200] 
Todor, I.; Popa, A.; Neag, M.; Muntean, D.; Bocsan, C.; Buzoianu, A.; Vlase, L.; Gheldiu, A.M.; Briciu, C. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J. Pharm. Pharm. Sci.,  2016, 19(2), 198-207.
[http://dx.doi.org/10.18433/J3H03R] [PMID:  27518170] 
[201] 
Kasi, P.M.; Mounzer, R.; Gleeson, G.H. Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep. Med.,  2011, •••2011952584
[http://dx.doi.org/10.1155/2011/952584] [PMID:  21765848] 
[202] 
Belle, D.J.; Ernest, C.S.; Sauer, J.M.; Smith, B.P.; Thomasson, H.R.; Witcher, J.W. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J. Clin. Pharmacol.,  2002, 42(11), 1219-1227.
[http://dx.doi.org/10.1177/009127002762491307] [PMID:  12412820] 
[203] 
Reed, V.A.; Buitelaar, J.K.; Anand, E.; Day, K.A.; Treuer, T.; Upadhyaya, H.P.; Coghill, D.R.; Kryzhanovskaya, L.A.; Savill, N.C. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A comprehensive review of over a decade of research. CNS Drugs,  2016, 30(7), 603-628.
[http://dx.doi.org/10.1007/s40263-016-0349-0] [PMID:  27290715] 
[204] 
Belkin, M.R.; Schwartz, T.L. Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder. Drugs Context,  2015, 4212286
[http://dx.doi.org/10.7573/dic.212286] [PMID:  26322115] 
[205] 
Strange, B.C. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr. Dis. Treat.,  2008, 4(3), 499-506.
[http://dx.doi.org/10.2147/NDT.S1711] [PMID:  18830439] 
[206] 
Taylor, F.B.; Russo, J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol.,  2001, 21(2), 223-228.
[http://dx.doi.org/10.1097/00004714-200104000-00015] [PMID:  11270920] 
[207] 
Butterfield, M.E.; Saal, J.; Young, B.; Young, J.L. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. Psychiatry Res.,  2016, 236, 136-141.
[http://dx.doi.org/10.1016/j.psychres.2015.12.017] [PMID:  26730446] 
[208] 
Kim, R.K.; Chayer, R. Psychosis associated with guanfacine. J. Clin. Psychopharmacol.,  2015, 35(2), 213.
[http://dx.doi.org/10.1097/JCP.0000000000000281] [PMID:  25679136] 
[209] 
Boreman, C.D.; Arnold, L.E. Hallucinations associated with initiation of guanfacine. J. Am. Acad. Child Adolesc. Psychiatry,  2003, 42(12), 1387.
[http://dx.doi.org/10.1097/00004583-200312000-00004] [PMID:  14627872] 
[210] 
Horrigan, J.P.; Barnhill, L.J. Guanfacine and secondary mania in children. J. Affect. Disord.,  1999, 54(3), 309-314.
[http://dx.doi.org/10.1016/S0165-0327(98)00183-9] [PMID:  10467976] 
[211] 
Elbe, D.; Perel-Panar, C.; Wicholas, L. Manic reaction in a child induced by guanfacine-extended release. J. Child Adolesc. Psychopharmacol.,  2016, 26(6), 566-567.
[http://dx.doi.org/10.1089/cap.2016.0050] [PMID:  27228067] 
[212] 
Fitzgerald, P.J. Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: Alcohol, nicotine, marijuana, heroin, cocaine, and caffeine. Subst. Abuse,  2013, 7, 171-183.
[http://dx.doi.org/10.4137/SART.S13019] [PMID:  24151426] 
[213] 
Gourlay, S.G.; Stead, L.F.; Benowitz, N.L. Clonidine for smoking cessation. Cochrane Database Syst. Rev., 2004, (3)CD000058
[PMID:  15266422] 
[214] 
Ziegenhorn, A.A.; Roepke, S.; Schommer, N.C.; Merkl, A.; Danker-Hopfe, H.; Perschel, F.H.; Heuser, I.; Anghelescu, I.G.; Lammers, C.H. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol.,  2009, 29(2), 170-173.
[http://dx.doi.org/10.1097/JCP.0b013e31819a4bae] [PMID:  19512980] 
[215] 
Fragkos, K.C.; Zárate-Lopez, N.; Frangos, C.C. What about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humans. Therap. Adv. Gastroenterol.,  2016, 9(3), 282-301.
[http://dx.doi.org/10.1177/1756283X15625586] [PMID:  27134659] 
[216] 
Li, L.; Xu, L.; Wu, J.; Dong, L.; Zhao, S.; Zheng, Q. Comparative efficacy of nonhormonal drugs on menopausal hot flashes. Eur. J. Clin. Pharmacol.,  2016, 72(9), 1051-1058.
[http://dx.doi.org/10.1007/s00228-016-2090-5] [PMID:  27450233] 
[217] 
Patel, S.S.; Dunn, C.J.; Bryson, H.M. Epidural Clonidine. CNS Drugs,  1996, 6(6), 474-497.
[http://dx.doi.org/10.2165/00023210-199606060-00007] 
[218] 
Kukoyi, A.; Coker, S.; Lewis, L.; Nierenberg, D. Two cases of acute dexmedetomidine withdrawal syndrome following prolonged infusion in the intensive care unit: Report of cases and review of the literature. Hum. Exp. Toxicol.,  2013, 32(1), 107-110.
[http://dx.doi.org/10.1177/0960327112454896] [PMID:  23111887] 
[219] 
Rulong, G.; Dye, T.; Simakajornboon, N. Pharmacological management of restless legs syndrome and periodic limb movement disorder in children. Paediatr. Drugs,  2018, 20(1), 9-17.
[http://dx.doi.org/10.1007/s40272-017-0262-0] [PMID:  28831753] 
[220] 
Croxtall, J.D. Clonidine extended-release: in attention-deficit hyperactivity disorder. Paediatr. Drugs,  2011, 13(5), 329-336.
[http://dx.doi.org/10.2165/11208100-000000000-00000] [PMID:  21888447] 
[221] 
Molina-Carballo, A.; Checa-Ros, A.; Muñoz-Hoyos, A. Treatments and compositions for attention deficit hyperactivity disorder: a patent review. Expert Opin. Ther. Pat.,  2016, 26(7), 799-814.
[http://dx.doi.org/10.1080/13543776.2016.1182989] [PMID:  27138211] 
[222] 
Attention Deficit Hyperactivity Disorder in Children and
Adolescents. In: Comparative Effectiveness Review Summary Guides for Clinicians, Rockville (MD), 2007. Available at: https://www.ncbi.nlm.nih.gov/books/NBK99165/(Accessed Date: January 31st, . 2018).
[223] 
Clonidine 25mcg Tablets BP. Available at: https://www.medicines.org.uk/emc/product/6538 [Accessed:December 8th, 2017]
[224] 
Perrine, D.M.; Ross, J.T.; Nervi, S.J.; Zimmerman, R.H.A. Short, one-pot synthesis of bupropion (Zyban, Wellbutrin). J. Chem. Educ.,  2000, 77(11), 1479.
[http://dx.doi.org/10.1021/ed077p1479] 
[225] 
Fava, M.; Rush, A.J.; Thase, M.E.; Clayton, A.; Stahl, S.M.; Pradko, J.F.; Johnston, J.A. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim. Care Companion J. Clin. Psychiatry,  2005, 7(3), 106-113.
[http://dx.doi.org/10.4088/PCC.v07n0305] [PMID:  16027765] 
[226] 
Moreira, R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin. Drug Investig.,  2011, 31(Suppl. 1), 5-17.
[http://dx.doi.org/10.2165/1159616-S0-000000000-00000] [PMID:  22015858] 
[227] 
Higgins, A.; Nash, M.; Lynch, A.M. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc. Patient Saf.,  2010, 2, 141-150.
[http://dx.doi.org/10.2147/DHPS.S7634] [PMID:  21701626] 
[228] 
Baldwin, D.S.; Papakostas, G.I. Symptoms of fatigue and sleepiness in major depressive disorder. J. Clin. Psychiatry,  2006, 67(Suppl. 6), 9-15.
[PMID:  16848671] 
[229] 
Pandhare, A.; Pappu, A. S.; Wilms, H.; Blanton, M. P.; Jansen, M. The antidepressant bupropion is a negative allosteric
modulator of serotonin type 3A receptors. Neuropharmacology 2017, 113(Pt A), 89-99.
[http://dx.doi.org/10.1016/j.neuropharm.2016.09.021] [PMID:  27671323] 
[230] 
Wilens, T.E.; Prince, J.B.; Spencer, T.; Van Patten, S.L.; Doyle, R.; Girard, K.; Hammerness, P.; Goldman, S.; Brown, S.; Biederman, J. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol. Psychiatry,  2003, 54(1), 9-16.
[http://dx.doi.org/10.1016/S0006-3223(02)01664-5] [PMID:  12842303] 
[231] 
Ishizuka, T.; Murotani, T.; Yamatodani, A. Action of modafinil through histaminergic and orexinergic neurons. Vitam. Horm.,  2012, 89, 259-278.
[http://dx.doi.org/10.1016/B978-0-12-394623-2.00014-7] [PMID:  22640618] 
[232] 
Goss, A.J.; Kaser, M.; Costafreda, S.G.; Sahakian, B.J.; Fu, C.H. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Psychiatry,  2013, 74(11), 1101-1107.
[http://dx.doi.org/10.4088/JCP.13r08560] [PMID:  24330897] 
[233] 
Menza, M.A.; Kaufman, K.R.; Castellanos, A. Modafinil augmentation of antidepressant treatment in depression. J. Clin. Psychiatry,  2000, 61(5), 378-381.
[http://dx.doi.org/10.4088/JCP.v61n0510] [PMID:  10847314] 
[234] 
Ketter, T.A.; Yang, R.; Frye, M.A. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J. Affect. Disord.,  2015, 181, 87-91.
[http://dx.doi.org/10.1016/j.jad.2015.04.012] [PMID:  25933099] 
[235] 
MacDonald, J.R.; Hill, J.D.; Tarnopolsky, M.A. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology,  2002, 59(12), 1876-1880.
[http://dx.doi.org/10.1212/01.WNL.0000037481.08283.51] [PMID:  12499477] 
[236] 
Hurst, D.L.; Lajara-Nanson, W. Use of modafinil in spastic cerebral palsy. J. Child Neurol.,  2002, 17(3), 169-172.
[http://dx.doi.org/10.1177/088307380201700303] [PMID:  12026230] 
[237] 
Nieves, A.V.; Lang, A.E. Treatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinil. Clin. Neuropharmacol.,  2002, 25(2), 111-114.
[http://dx.doi.org/10.1097/00002826-200203000-00010] [PMID:  11981239] 
[238] 
Abbas, G.; Jorgensen, R.A.; Lindor, K.D. Fatigue in primary biliary cirrhosis. Nat. Rev. Gastroenterol. Hepatol.,  2010, 7(6), 313-319.
[http://dx.doi.org/10.1038/nrgastro.2010.62] [PMID:  20458334] 
[239] 
Loland, C.J.; Mereu, M.; Okunola, O.M.; Cao, J.; Prisinzano, T.E.; Mazier, S.; Kopajtic, T.; Shi, L.; Katz, J.L.; Tanda, G.; Newman, A.H. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol. Psychiatry,  2012, 72(5), 405-413.
[http://dx.doi.org/10.1016/j.biopsych.2012.03.022] [PMID:  22537794] 
[240] 
Chatterjie, N.; Stables, J.P.; Wang, H.; Alexander, G.J. Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity. Neurochem. Res.,  2004, 29(8), 1481-1486.
[http://dx.doi.org/10.1023/B:NERE.0000029559.20581.1a] [PMID:  15260124] 
[241] 
Robertson, P.; DeCory, H.H.; Madan, A.; Parkinson, A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab. Dispos.,  2000, 28(6), 664-671.
[PMID:  10820139] 
[242] 
Reith, M.E.; Blough, B.E.; Hong, W.C.; Jones, K.T.; Schmitt, K.C.; Baumann, M.H.; Partilla, J.S.; Rothman, R.B.; Katz, J.L. Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend.,  2015, 147, 1-19.
[http://dx.doi.org/10.1016/j.drugalcdep.2014.12.005] [PMID:  25548026] 
[243] 
Kolar, D.; Keller, A.; Golfinopoulos, M.; Cumyn, L.; Syer, C.; Hechtman, L. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr. Dis. Treat.,  2008, 4(2), 389-403.
[PMID:  18728745] 
[244] 
Spencer, T.; Biederman, J.; Wilens, T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr. Clin. North Am.,  2004, 27(2), 373-383.
[http://dx.doi.org/10.1016/j.psc.2003.12.001] [PMID:  15064003] 
[245] 
Findling, R.L.; McNamara, N.K.; Stansbrey, R.; Gracious, B.L.; Whipkey, R.E.; Demeter, C.A.; Reed, M.D.; Youngstrom, E.A.; Calabrese, J.R. Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization. J. Am. Acad. Child Adolesc. Psychiatry,  2006, 45(2), 142-148.
[http://dx.doi.org/10.1097/01.chi.0000189135.05060.8a] [PMID:  16429084] 
[246] 
Buoli, M.; Serati, M.; Cahn, W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev. Neurother.,  2016, 16(2), 131-144.
[http://dx.doi.org/10.1586/14737175.2016.1135735] [PMID:  26693882] 
[247] 
Chen, Z.; Skolnick, P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin. Investig. Drugs,  2007, 16(9), 1365-1377.
[http://dx.doi.org/10.1517/13543784.16.9.1365] [PMID:  17714023] 
[248] 
A., Randomized  Double Blind, Multicenter, Placebo Controlled,
Parallel Group, Efficacy and Safety Study of 2
Doses of Dasotraline in Adults With Attention Deficit Hyperactivity
Disorder (ADHD). Available at: https://www.clinicaltrials.gov/show/NCT02276209 [Accessed: December 8th, 2017]
[249] 
Koblan, K.S.; Hopkins, S.C.; Sarma, K.; Jin, F.; Goldman, R.; Kollins, S.H.; Loebel, A. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology,  2015, 40(12), 2745-2752.
[http://dx.doi.org/10.1038/npp.2015.124] [PMID:  25948101] 
[250] 
Kaufmann, H.; Freeman, R.; Biaggioni, I.; Low, P.; Pedder, S.; Hewitt, L.A.; Mauney, J.; Feirtag, M.; Mathias, C.J.; Investigators, N.O.H. Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial. Neurology,  2014, 83(4), 328-335.
[http://dx.doi.org/10.1212/WNL.0000000000000615] [PMID:  24944260] 
[251] 
Adler, L.A.; Gorny, S.W. Pilot study of droxidopa with carbidopa in adults with ADHD. J. Atten. Disord.,  2015, 23(2), 189-198.
[http://dx.doi.org/10.1177/1087054715580393] [PMID:  25907673] 
[252] 
Bymaster, F.P.; Dreshfield-Ahmad, L.J.; Threlkeld, P.G.; Shaw, J.L.; Thompson, L.; Nelson, D.L.; Hemrick-Luecke, S.K.; Wong, D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology,  2001, 25(6), 871-880.
[http://dx.doi.org/10.1016/S0893-133X(01)00298-6] [PMID:  11750180] 
[253] 
Riahi, F.; Tehrani-Doost, M.; Shahrivar, Z.; Alaghband-Rad, J. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Hum. Psychopharmacol.,  2010, 25(7-8), 570-576.
[http://dx.doi.org/10.1002/hup.1158] [PMID:  21312292] 
[254] 
Hashemian, F.; Mohammadian, S.; Riahi, F.; Ghaeli, P.; Ghodsi, D. A comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD). Daru,  2011, 19(3), 231-235.
[PMID:  22615662] 
[255] 
Hedges, D.; Reimherr, F.W.; Rogers, A.; Strong, R.; Wender, P.H. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol. Bull.,  1995, 31(4), 779-783.
[PMID:  8851653] 
[256] 
Amiri, S.; Farhang, S.; Ghoreishizadeh, M.A.; Malek, A.; Mohammadzadeh, S. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum. Psychopharmacol.,  2012, 27(1), 76-81.
[http://dx.doi.org/10.1002/hup.1274] [PMID:  22252909] 
[257] 
Adler, L.A.; Resnick, S.; Kunz, M.; Devinsky, O. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol. Bull.,  1995, 31(4), 785-788.
[PMID:  8851654] 
[258] 
Findling, R.L.; Schwartz, M.A.; Flannery, D.J.; Manos, M.J. Venlafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial. J. Clin. Psychiatry,  1996, 57(5), 184-189.
[PMID:  8626348] 
[259] 
Manor, I.; Rubin, J.; Daniely, Y.; Adler, L.A. Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD. Postgrad. Med.,  2014, 126(5), 7-16.
[http://dx.doi.org/10.3810/pgm.2014.09.2795] [PMID:  25295645] 
[260] 
260] The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD.Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT02477748 [Accessed: December 8th, 2017]
[261] 
Sandra Kooij, J.J.; Marije Boonstra, A.; Swinkels, S.H.; Bekker, E.M.; de Noord, I.; Buitelaar, J.K. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J. Atten. Disord.,  2008, 11(4), 445-458.
[http://dx.doi.org/10.1177/1087054707299367] [PMID:  18083961] 
[262] 
Biederman, J.; Faraone, S.V.; Spencer, T.; Wilens, T.; Norman, D.; Lapey, K.A.; Mick, E.; Lehman, B.K.; Doyle, A. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry,  1993, 150(12), 1792-1798.
[http://dx.doi.org/10.1176/ajp.150.12.1792] [PMID:  8238632] 
[263] 
Wilens, T.E.; Biederman, J.; Faraone, S.V.; Martelon, M.; Westerberg, D.; Spencer, T.J. Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J. Clin. Psychiatry,  2009, 70(11), 1557-1562.
[http://dx.doi.org/10.4088/JCP.08m04785pur] [PMID:  20031097] 
[264] 
Gibbins, C.; Weiss, M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr. Psychiatry Rep.,  2007, 9(5), 420-426.
[http://dx.doi.org/10.1007/s11920-007-0055-1] [PMID:  17915083] 
[265] 
Mannuzza, S.; Klein, R.G.; Klein, D.F.; Bessler, A.; Shrout, P. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. Am. J. Psychiatry,  2002, 159(11), 1882-1888.
[http://dx.doi.org/10.1176/appi.ajp.159.11.1882] [PMID:  12411223] 
[266] 
Belendiuk, K.A.; Clarke, T.L.; Chronis, A.M.; Raggi, V.L. Assessing the concordance of measures used to diagnose adult ADHD. J. Atten. Disord.,  2007, 10(3), 276-287.
[http://dx.doi.org/10.1177/1087054706289941] [PMID:  17242423] 
[267] 
Najt, P.; Glahn, D.; Bearden, C.E.; Hatch, J.P.; Monkul, E.S.; Kaur, S.; Villarreal, V.; Bowden, C.; Soares, J.C. Attention deficits in bipolar disorder: a comparison based on the continuous performance test. Neurosci. Lett.,  2005, 379(2), 122-126.
[http://dx.doi.org/10.1016/j.neulet.2004.12.051] [PMID:  15823428] 
[268] 
Bora, E.; Vahip, S.; Akdeniz, F. Sustained attention deficits in manic and euthymic patients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry,  2006, 30(6), 1097-1102.
[http://dx.doi.org/10.1016/j.pnpbp.2006.04.016] [PMID:  16740350] 
[269] 
Swann, A.C.; Lijffijt, M.; Lane, S.D.; Steinberg, J.L.; Moeller, F.G. Increased trait-like impulsivity and course of illness in bipolar disorder. Bipolar Disord.,  2009, 11(3), 280-288.
[http://dx.doi.org/10.1111/j.1399-5618.2009.00678.x] [PMID:  19419385] 
[270] 
Strakowski, S.M.; Fleck, D.E.; DelBello, M.P.; Adler, C.M.; Shear, P.K.; Kotwal, R.; Arndt, S. Impulsivity across the course of bipolar disorder. Bipolar Disord.,  2010, 12(3), 285-297.
[http://dx.doi.org/10.1111/j.1399-5618.2010.00806.x] [PMID:  20565435] 
[271] 
Perroud, N.; Cordera, P.; Zimmermann, J.; Michalopoulos, G.; Bancila, V.; Prada, P.; Dayer, A.; Aubry, J.M. Comorbidity between attention deficit hyperactivity disorder (ADHD) and bipolar disorder in a specialized mood disorders outpatient clinic. J. Affect. Disord.,  2014, 168, 161-166.
[http://dx.doi.org/10.1016/j.jad.2014.06.053] [PMID:  25051093] 
[272] 
Paelecke-Habermann, Y.; Pohl, J.; Leplow, B. Attention and executive functions in remitted major depression patients. J. Affect. Disord.,  2005, 89(1-3), 125-135.
[http://dx.doi.org/10.1016/j.jad.2005.09.006] [PMID:  16324752] 
[273] 
Malhi, G.S.; Ivanovski, B.; Hadzi-Pavlovic, D.; Mitchell, P.B.; Vieta, E.; Sachdev, P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord.,  2007, 9(1-2), 114-125.
[http://dx.doi.org/10.1111/j.1399-5618.2007.00324.x] [PMID:  17391355] 
[274] 
Jaideep, T.; Reddy, Y.C.; Srinath, S. Comorbidity of attention deficit hyperactivity disorder in juvenile bipolar disorder. Bipolar Disord.,  2006, 8(2), 182-187.
[http://dx.doi.org/10.1111/j.1399-5618.2006.00293.x] [PMID:  16542189] 
[275] 
Sachs, G.S.; Baldassano, C.F.; Truman, C.J.; Guille, C. Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder. Am. J. Psychiatry,  2000, 157(3), 466-468.
[http://dx.doi.org/10.1176/appi.ajp.157.3.466] [PMID:  10698829] 
[276] 
Masi, G.; Perugi, G.; Toni, C.; Millepiedi, S.; Mucci, M.; Bertini, N.; Pfanner, C. Attention-deficit hyperactivity disorder -- bipolar comorbidity in children and adolescents. Bipolar Disord.,  2006, 8(4), 373-381.
[http://dx.doi.org/10.1111/j.1399-5618.2006.00342.x] [PMID:  16879138] 
[277] 
Sentissi, O.; Navarro, J.C.; De Oliveira, H.; Gourion, D.; Bourdel, M.C.; Baylé, F.J.; Olié, J.P.; Poirier, M.F. Bipolar disorders and quality of life: the impact of attention deficit/hyperactivity disorder and substance abuse in euthymic patients. Psychiatry Res.,  2008, 161(1), 36-42.
[http://dx.doi.org/10.1016/j.psychres.2007.06.016] [PMID:  18786727] 
[278] 
Brand, S.; Gerber, M.; Pühse, U.; Holsboer-Trachsler, E. ‘Bright side’ and ‘dark side’ hypomania are associated with differences in psychological functioning, sleep and physical activity in a non-clinical sample of young adults. J. Affect. Disord.,  2011, 131(1-3), 68-78.
[http://dx.doi.org/10.1016/j.jad.2010.12.007] [PMID:  21227510] 
[279] 
Jahangard, L.; Rahmani, A.; Haghighi, M.; Ahmadpanah, M.; Sadeghi Bahmani, D.; Soltanian, A.R.; Shirzadi, S.; Bajoghli, H.; Gerber, M.; Holsboer-Trachsler, E.; Brand, S. “Always Look on the Bright Side of Life!” - higher hypomania scores are associated with higher mental toughness, increased physical activity, and lower symptoms of depression and lower sleep complaints. Front. Psychol.,  2017, 8, 2130.
[http://dx.doi.org/10.3389/fpsyg.2017.02130] [PMID:  29312026] 
[280] 
Mueller, A.; Hong, D.S.; Shepard, S.; Moore, T. Linking ADHD to the neural circuitry of attention. Trends Cogn.Sci. (Regul. Ed.),,  2017, 21(6), 474-488.
[http://dx.doi.org/10.1016/j.tics.2017.03.009] [PMID:  28483638] 
[281] 
Mucci, N.; Giorgi, G.; De Pasquale Ceratti, S.; Fiz-Pérez, J.; Mucci, F.; Arcangeli, G. Anxiety, stress-related factors, and blood pressure in young adults. Front. Psychol.,  2016, 7, 1682.
[http://dx.doi.org/10.3389/fpsyg.2016.01682] [PMID:  27840615] 
[282] 
Richard-Lepouriel, H.; Etain, B.; Hasler, R.; Bellivier, F.; Gard, S.; Kahn, J.P.; Prada, P.; Nicastro, R.; Ardu, S.; Dayer, A.; Leboyer, M.; Aubry, J.M.; Perroud, N.; Henry, C. Similarities between emotional dysregulation in adults suffering from ADHD and bipolar patients. J. Affect. Disord.,  2016, 198, 230-236.
[http://dx.doi.org/10.1016/j.jad.2016.03.047] [PMID:  27031290] 
[283] 
Marin, A.; Scott, D.; Groll, D.L. Bipolar disorder comorbid
with attention-deficit/hyperactivity disorder in adult inpatients
with acute relapse. Prim. Care Companion CNS Disord.,,  2013, 15(4), PCC.12m01495..
[http://dx.doi.org/10.4088/PCC.12m01495] [PMID:  24392249] 
[284] 
Tamam, L.; Karakus, G.; Ozpoyraz, N. Comorbidity of adult attention-deficit hyperactivity disorder and bipolar disorder: prevalence and clinical correlates. Eur. Arch. Psychiatry Clin. Neurosci.,  2008, 258(7), 385-393.
[http://dx.doi.org/10.1007/s00406-008-0807-x] [PMID:  18437277] 
[285] 
Biederman, J.; Petty, C.R.; Monuteaux, M.C.; Mick, E.; Clarke, A.; Ten Haagen, K.; Faraone, S.V. Familial risk analysis of the association between attention-deficit/hyperactivity disorder and psychoactive substance use disorder in female adolescents: a controlled study. J. Child Psychol. Psychiatry,  2009, 50(3), 352-358.
[http://dx.doi.org/10.1111/j.1469-7610.2008.02040.x] [PMID:  19309331] 
[286] 
Adler, L.A. Familial transmission of ADHD and psychoactive substance use disorders. Am. J. Psychiatry,  2008, 165(1), 11-12.
[http://dx.doi.org/10.1176/appi.ajp.2007.07101614] [PMID:  18178750] 
[287] 
Rabiner, D.L. Stimulant prescription cautions: addressing misuse, diversion and malingering. Curr. Psychiatry Rep.,  2013, 15(7), 375.
[http://dx.doi.org/10.1007/s11920-013-0375-2] [PMID:  23712725] 
[288] 
Aita, S.L.; Sofko, C.A.; Hill, B.D.; Musso, M.W.; Boettcher, A.C. Utility of the personality assessment inventory in detecting feigned Attention-Deficit/Hyperactivity Disorder (ADHD): The feigned adult ADHD index. Arch. Clin. Neuropsychol.,  2018, 33(7), 832-844.
[http://dx.doi.org/10.1093/arclin/acx113] [PMID:  29186287] 
[289] 
Clemow, D.B. Misuse of methylphenidate. Curr. Top. Behav. Neurosci.,  2017, 34, 99-124.
[http://dx.doi.org/10.1007/7854_2015_426] [PMID:  26695166] 
[290] 
Upadhyaya, H.P.; Kroutil, L.A.; Deas, D.; Durell, T.M.; Van Brunt, D.L.; Novak, S.P. Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population. Am. J. Addict.,  2010, 19(6), 569-577.
[http://dx.doi.org/10.1111/j.1521-0391.2010.00078.x] [PMID:  20958854] 
[291] 
Judson, R.; Langdon, S.W. Illicit use of prescription stimulants among college students: prescription status, motives, theory of planned behaviour, knowledge and self-diagnostic tendencies. Psychol. Health Med.,  2009, 14(1), 97-104.
[http://dx.doi.org/10.1080/13548500802126723] [PMID:  19085316] 
Rights & Permissions Print Cite
Article Metrics
89
15
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0929867326666190805153610	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X
Current Medicinal Chemistry

ADHD with Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical and Pharmacological Aspects Across the Lifespan

Abstract

Related Journals

Related Books

Related Articles
